<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Summers, Jaye</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Macdonell, Richard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Teriflunomide Associated With Reductions in Severe MS Relapses</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">The TEMSO and TOWER trials demonstrate that both doses of teriflunomide (7 mg and 14 mg) each significantly reduce the annualized relapse rates in patients with relapsing multiple sclerosis. Post hoc analyses of both trials indicate that only teriflunomide 14 mg significantly reduces the rate of all 5 markers of severe relapse in both studies.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>